Inhalable vaccine of bacterial culture supernatant extract mediates protection against fatal pulmonary anthrax
Authors:
Open Access
- 31 March 2023
- journal article
- research article
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 12 (1) , 2191741
Abstract
Pulmonary anthrax is the most fatal clinical form of anthrax and currently available injectable vaccines do not provide adequate protection against it. Hence, next-generation vaccines that effectively induce immunity against pulmonary anthrax are urgently needed. In the present study, we prepared an attenuated and low protease activity Bacillus anthracis strain A16R-5.1 by deleting five of its extracellular protease activity-associated genes and its lef gene through the CRISPR-Cas9 genome editing system. This mutant strain was then used to formulate a lethal toxin (LeTx)-free culture supernatant extract (CSE) anthrax vaccine,of which half was protective antigen (PA). We generated liquid, powder, and powder reconstituted formulations that could be delivered by aerosolized intratracheal inoculation. All of them induced strong humoral, cellular, and mucosal immune responses. The vaccines also produced LeTx neutralizing antibodies and conferred full protection against the lethal aerosol challenges of B. anthracis Pasteur II spores in mice. Compared to the recombinant PA vaccine, the CSE anthrax vaccine with equal PA content provided superior immunoprotection against pulmonary anthrax. The preceding results suggest that the CSE anthrax vaccine developed herein is suitable and scalable for use in inhalational immunization against pulmonary anthrax.Keywords
This publication has 46 references indexed in Scilit:
- A Three-Dose Intramuscular Injection Schedule of Anthrax Vaccine Adsorbed Generates Sustained Humoral and Cellular Immune Responses to Protective Antigen and Provides Long-Term Protection against Inhalation Anthrax in Rhesus MacaquesClinical and Vaccine Immunology, 2012
- Stable Dry Powder Formulation for Nasal Delivery of Anthrax VaccineJournal of Pharmaceutical Sciences, 2012
- Anthrax: an updateAsian Pacific Journal of Tropical Biomedicine, 2011
- Membrane translocation by anthrax toxinMolecular Aspects of Medicine, 2009
- Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990–2007 [Vaccine 2009;27:290–297]Vaccine, 2009
- Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccineExpert Opinion on Biological Therapy, 2009
- Efficacy of a Vaccine Based on Protective Antigen and Killed Spores against Experimental Inhalational AnthraxInfection and Immunity, 2009
- The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune responseImmunology, 2007
- Differential Proteomic Analysis of theBacillus anthracisSecretome: Distinct Plasmid and Chromosome CO2-Dependent Cross Talk Mechanisms Modulate Extracellular Proteolytic ActivitiesJournal of Bacteriology, 2006
- Molecular basis for improved anthrax vaccinesAdvanced Drug Delivery Reviews, 2005